JPRN-jRCTs031200222招募中未知
The efficacy of tamoxifen to prevent the incidence of breast cancer in Japanese women with pathogenic mutations of BRCA2
akamura Seigo0 个研究点目标入组 210 人开始时间: 2020年11月30日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 70age old（—）
- 性别
- Female
入选标准
- •1)Women of age >= 20 and <=70 years at enrollment
- •2)Women with a confirmed deleterious BRCA2 germline mutation
- •3)No evidence of breast cancer by mammography and breast ultrasound with latest examination prior to enrollment
- •4)ECOG performance status (PS) is 0 or 1
- •5)Women who do not wish or plan for preventive mastectomy
- •6)Women who have major organ functions
- •7)Women who have written informed consent to participate in this study
- •Genetic tests tested outside of Japan will be those that meet CLIA criteria.
排除标准
- •1)Women who underwent bilateral mastectomy
- •2)History of invasive breast cancer or non-invasive ductal carcinoma
- •3)History of invasive cancer except for basal cell carcinoma, spinous cell carcinoma, carcinoma in situ of the cervix, papilla cancer or follicular cancer
- •4)Any medical or psychiatric condition that may prevent the subject from completing the study
- •5)Women who are judged inappropriate to participate the study by the investigator
研究者
相似试验
撤回
不适用
The protective effect of tamoxifen in women with ER-positive breast cancer who opt for cryopreservation of oocytes or embryos: a prospectively controlled study.mammary carcinoma1000629110018515breast cancerNL-OMON36860Academisch Medisch Centrum40
已完成
2 期
Evaluation of the effects of increasing tamoxifen dose on the treatment process in breast cancer patientsBreast cancer.Malignant neoplasm of breastIRCT2015082323734N1Isfahan University of Medical Siences100
撤回
4 期
Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot TrialVaginal BleedingNCT04933240Virginia Commonwealth University
已完成
3 期
Phase III Randomized Adjuvant Study of Tamoxifen Alone Versus Sequential Tamoxifen and Anastrozole in Hormone-Responsive Postmenopausal Breast Cancer PatientsHormone-responsive postmenopausal primary breast cancerJPRN-C000000056-SAS BC 03 executive committee2,500
进行中（未招募）
不适用
Optimizing tamoxifen therapy through the induction of CYP3A4, CYP2C and CYP2D6 mediated metabolism - Induction of tamoxifen metabolismMedDRA version: 12.1Level: LLTClassification code 10006187Term: Breast cancerBreast cancerEUCTR2010-023776-52-NL12